This study provides clinical evidence for IL-17 pathway-targeted therapy in patients with congenital ichthyosis characterized by inflammatory phenotypes, highlighting the critical role of IL17A in the disease's immune mechanisms, and aiding in the development of precision strategies for future biologic applications.
Literature Overview
The article titled 'Real-World Effectiveness of Secukinumab in Congenital Ichthyoses: A Retrospective Monocentric Case Series,' published in the journal Antibodies, systematically investigates the long-term real-world efficacy and safety of secukinumab—a biologic targeting IL17A—in adult patients with severe congenital ichthyosis (CI). Through a retrospective cohort analysis, the study reveals significant improvement in inflammatory skin manifestations, particularly rapid alleviation of erythema and pruritus, thereby introducing an immune-regulatory dimension to the traditional disease model centered on keratinization abnormalities.Background Knowledge
Congenital ichthyosis (CI) is a group of rare inherited skin disorders characterized by epidermal differentiation defects, barrier dysfunction, and chronic scaling. Conventional treatments rely on emollients, keratolytics, and systemic retinoids, which often yield limited efficacy in some patients. Recently, abnormal activation of the IL23/Th17 axis has been identified across multiple CI subtypes (e.g., lamellar ichthyosis, congenital ichthyosiform erythroderma), suggesting that IL17A may act as a key effector cytokine driving inflammation. Although IL17A inhibitors are well established in psoriasis, their application in CI remains exploratory, with a lack of long-term real-world data. Current challenges include: how to identify CI phenotypes responsive to immunotherapy, and how to balance treatment goals between structural abnormalities and inflammatory responses? This study addresses these unmet clinical needs by evaluating the real-world effectiveness and durability of IL17A inhibition in CI, offering preliminary evidence for mechanism-driven personalized therapy.
Research Methods and Experiments
The study employed a single-center, retrospective case series design, enrolling eight adult CI patients (seven with lamellar ichthyosis, one with Chanarin–Dorfman syndrome), all of whom received secukinumab (300 mg, subcutaneous injection every four weeks) for at least six months, with a maximum follow-up of 56 months. Clinical assessments were conducted by the same experienced dermatologist during routine visits, using the Investigator Global Assessment (IGA) scale to evaluate erythema, truncal/limb scaling, scalp scaling, and palmoplantar hyperkeratosis. Pruritus was assessed using the Numeric Rating Scale (NRS). Data were analyzed longitudinally across predefined timepoints (T1 to T10), focusing on early and long-term efficacy changes. All patients underwent genetic testing at baseline, although original molecular reports were not uniformly available, limiting genotype–phenotype correlation analysis.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides real-world evidence supporting a shift in the treatment paradigm for congenital ichthyosis from 'symptomatic management' to 'mechanism-targeted therapy.' It emphasizes viewing CI as a systemic disorder involving both structural and inflammatory components, rather than merely a keratinization defect. Future drug development should explore multi-target strategies, such as combining IL17A inhibition with keratolytic agents, or investigating biologics targeting upstream IL23 to intervene earlier in the immune axis. Additionally, predictive biomarkers (e.g., skin transcriptomic profiles, serum IL-17 levels) should be established to identify potential responders and advance precision medicine approaches.
Conclusion
This study, based on real-world data, reveals that secukinumab, an IL17A-targeting biologic, demonstrates significant and sustained efficacy against inflammatory manifestations such as erythema and pruritus in patients with congenital ichthyosis, while showing limited improvement in structural lesions such as palmoplantar hyperkeratosis. This suggests clinicians should adopt stratified treatment approaches based on patient phenotype, prioritizing biologics for individuals with CI whose symptoms are predominantly inflammatory. These findings lay the foundation for developing personalized care pathways aligned with the 'phenotype-mechanism-treatment' model, advancing the management of rare skin disorders toward precision medicine. Future multicenter prospective studies are needed to validate efficacy and explore combination therapies to comprehensively improve quality of life in CI patients.
